SELLAS Life Sciences Group (SLS) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
16 Jun, 2026Opening remarks and agenda
The meeting was called to order virtually, with adherence to rules of conduct and an agenda provided online.
Directors, executive officers, legal counsel, and auditors were introduced at the outset.
Board and executive committee updates
Directors and committee chairs for Compensation, Science, Audit, and Nominating & Corporate Governance were present.
The board expressed appreciation for shareholder engagement and proxy submissions.
Shareholder proposals
Five proposals were presented: re-election of two directors, ratification of auditors, amendment to the equity plan, advisory vote on executive compensation, and approval for potential meeting adjournment.
Partial view of Summaries dataset, powered by Quartr API
Latest events from SELLAS Life Sciences Group
- Net loss rose to $18.0M in H1 2026; cash reached $138.3M as clinical programs advanced.SLS
Q2 2026 - Pivotal AML trial data for GPS and phase II results for SLS009 are expected to drive major milestones.SLS
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA - Pivotal data for GPS and SLS-009 in AML expected by year-end, backed by strong financials.SLS
A.G.P.'s Annual Virtual Healthcare Conference - Imminent phase III and II data for GPS and SLS009 in AML signal major near-term catalysts.SLS
Stifel 2026 Targeted Oncology Virtual Forum - Pivotal AML trials near key readouts as net loss rises and cash reserves strengthen.SLS
Q1 2026 - Annual meeting to vote on directors, auditor, equity plan, executive pay, and governance matters.SLS
Proxy filing - Virtual annual meeting to vote on directors, auditor, equity plan, and executive pay.SLS
Proxy filing - Strong cash position and clinical progress in AML set stage for pivotal 2026.SLS
Q4 2025 - GPS and SLS009 advance as late-stage, first-in-class AML therapies with pivotal data imminent.SLS
R&D Day 2025